News and Press Releases
Almac Group delivers record year of growth
Almac Group, the global contract pharmaceutical development and manufacturing organisation, has announced record financial results for the year ending 30 September 2025, with revenue, profit and employee numbers all reaching...
Category:
Posted: May 21, 2026
Cyclana Bio granted Health Research Authority approval and recruits first patients for clinical observational study in endometriosis
UK NHS grants HRA/REC approval for PEMP study with Peterborough and Cambridge hospitals Clinical observational study investigating underlying biology of endometriosis aims to uncover causal mechanisms and new druggable targets...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 19, 2026
Mestag Therapeutics Announces the First Patient Dosed with MST-0312 in the Phase I STARLYS Trial
STARLYS trial to evaluate the potential of MST-0312, a targeted lymphotoxin-beta (LTBR) agonist bispecific antibody, as a novel therapeutic strategy for the treatment of solid tumors Study to evaluate tertiary...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 19, 2026
Suite 15 Science Village, Chesterford Research Park, Little Chesterford, Cambridge, CB10 1XL UK
Microbiotica Announces Positive Results from its Phase 1b Trial (MELODY-1) of MB097, a Precision Microbiome Co-Therapy in Advanced Melanoma
MB097 used in combination with MSD’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab) 18 May 2026 -- Cambridge, UK -- Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 18, 2026
Microbiotica Limited Chesterford Research Park Little Chesterford Cambridge CB10 1XL UK
FASENRA approved in US for hypereosinophilic syndrome
14 May 2026 -- Cambridge, UK -- AstraZeneca’s FASENRA (benralizumab) has been approved by the US FDA for the treatment of adult and pediatric patients aged 12 years and older with...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 14, 2026
Chiesi Receives MHRA Approval for Additional Dosing Regimen of Elfabrio (pegunigalsidase alfa) 2mg/kg administered every-four-weeks in adults stable with an enzyme replacement therapy
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved an additional dosing regimen of 2mg/kg administered every-four-weeks for pegunigalsidase alfa in adults stable with an enzyme replacement therapy...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 14, 2026
NICE recommends WINREVAIR (Sotatercept) as a treatment option for adult patients in England and Wales with pulmonary arterial hypertension (PAH)
Sotatercept is indicated for use in combination with other pulmonary arterial hypertension (PAH) therapies, for the treatment of PAH in adult patients with WHO Functional Class (FC) II to III,...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: May 14, 2026
1 rue Jacques Monod, Site Montesquieu, 33650 Martillac, France
Veristat Launches AI Biostatistics Platform, Cutting Clinical Trial Data Readout Time from 5 Weeks to 5 Days* Without Regulatory Risks
Southborough, Massachusetts, US – May 13, 2026 –VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced the launch of InStatTM by Veristat. InStat is the...
Category:
Posted: May 14, 2026
Vetter Starts Construction of a New Production Site in Germany
Saarlouis / Ravensburg, May 13, 2026: Vetter, a leading Contract Development and Manufacturing Organization (CDMO), is celebrating the start of construction on its new site in Saarlouis with a traditional...
Category:
Posted: May 14, 2026
VoxCell BioInnovation and adMare BioInnovations Partner to Advance Novel Antibody Therapies in a Human-Relevant Vascularized Tissue Platform
Collaboration applies perfusable, immune-competent 3D bioprinted cancer tissue models to preclinical evaluation of next-generation oncology biologics, supporting the FDA’s push toward more predictive, human-relevant testing and reduced reliance on animal...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 13, 2026
Emerson Introduces Next-Generation Industrial Data Fabric, Providing Foundation for Highly Integrated Industrial Data Platform
Enhanced AspenTech Inmation OT Data Fabric to accelerate enterprise-scale intelligence 13 May 2026 -- Texas, US -- Global automation leader Emerson today announced major advancements to the AspenTech Inmation™ OT...
Category: Biotechnology, Other, Pharmaceutical
Posted: May 13, 2026
Neurizon Receives Ethics Approval for Phase 1 NUZ-001 Oral Liquid Formulation Study
Bellberry Human Research Ethics Committee (HREC) approves Neurizon’s Phase 1 formulation study supporting development of the NUZ-001 oral liquid formulation and continued advancement of NUZ-001 for amyotrophic lateral sclerosis (ALS)...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 13, 2026
Level 4, 96-100 Albert Road South Melbourne, VIC 3205 Australia
Brainomix and Boehringer Ingelheim Advance Strategic Partnership in Pulmonary Fibrosis
The two companies are broadening their partnership, building on strong results seen in the initial phase which demonstrated e-Lung’s potential to enable earlier diagnosis of progressive pulmonary fibrosis (PPF) Findings...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: May 12, 2026
Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001
First investigational inhaled ENaC blocker to deliver clinically relevant and statistically significant change in lung function compared to placebo Inhaled therapeutic designed to treat the 10% of people with cystic...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 12, 2026
Sussex Innovation Centre, University of Sussex, Science Park Square, Falmer, Brighton, BN1 9SB, UK
AOP Health and VRG Therapeutics Enter Co-Development Partnership for New Immunology Program
12 May 2026 -- Vienna, Austria and Budapest, Hungary -- AOP Health, a global pharmaceutical enterprise group focused on integrated therapies for rare diseases and critical care, today announced a strategic partnership...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: May 12, 2026
